Long-term Outcomes with Prostate Brachytherapy

13 modules

ABS Learning

13 Aug 2021




Brachytherapy refers to radiation treatment where radioactive material is placed adjacent to, or directly into, the tumor tissue. This is a surgical aspect of the Radiation Oncology speciality, and it requires additional training and expertise. 

Many tumor sites are treated with brachytherapy, including GYN, GI, breast, ocular melanoma, sarcoma, and penile cancer, as well as prostate cancer. Unlike in Europe and Canada, utilization of brachytherapy in the United States has decreased in recent years. The reasons may include the development of new technologies that do not require procedural expertise (e.g., SBRT), inadequate training, and/or inadequate remuneration. Yet we believe that brachytherapy is the most effective form of radiation treatment for prostate cancer.

In this series, we include presentations from the leading experts in the field of brachytherapy to discuss long-term disease outcomes, toxicity, socioeconomic issues, training, and new developments in the field.


  1. Mira Keyes, MD, FRCPC, FABS, British Columbia Cancer Agency (BCCA), Vancouver, British Columbia, Canada
  2. Steven J. Frank, MD​FABS, The University of Texas MD Anderson Cancer Center, Houston, Texas
  3. Timothy N. Showalter, MD, MPH, University of Virginia School of Medicine, Charlottesville, VA

  4. Brian J. Moran, MD​FABS, Chicago Prostate Center, Westmont, Illinois

  5. Juanita M. Crook, MD, FRCPC​FABS, University of British Columbia, Kelowna, British Columbia, Canada

  6. Michael J. Zelefsky, MD​FABS, Memorial Sloan Kettering Cancer Center, New York, New York

  7. Peter F. Orio, III, DO, MS​FABS, Dana Farber Cancer Institute, Milford, Massachusetts

  8. Daniel Petereit, MD, FASTRO​FABS, Dakota West Radiation Oncology, Rapid City, South Dakota

  9. Gerard Morton, MD​FABS, Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, Ontario


After completing Long-term Outcomes with Prostate Brachytherapy, the audience should gain knowledge on long-term outcomes with prostate brachytherapy in the treatment of prostate cancer.

Topic areas include:

  • long-term results in low, intermediate, and high-risk disease
  • PSA definition of cure with brachytherapy
  • socioeconomic aspects of treatment
  • training

The course will also help dispel several myths about brachytherapy and present the current state of randomized clinical trials.

Introduction - Mira Keyes, MD, FABS
{{ vm.helper.t('reports.module') }}
The Myths and Facts About Prostate Brachytherapy - Steven Frank, MD, FABS
{{ vm.helper.t('reports.module') }}
Long-term Outcomes with Monotherapy for LR and fIR Prostate Cancer - Timothy Showalter, MD
{{ vm.helper.t('reports.module') }}
Long-term Outcomes with Brachytherapy for Intermediate Risk Prostate Cancer - Steven Frank, MD, FABS
{{ vm.helper.t('reports.module') }}
Long-term Outcomes with Brachytherapy in High-Risk Prostate Cancer - Brian Moran, MD, FABS
{{ vm.helper.t('reports.module') }}
A Biochemical Definition of Cure Following Brachytherapy - Juanita Crook, MD, FABS
{{ vm.helper.t('reports.module') }}
Comparative Outcomes: Prostate Brachytherapy vs. EBRT vs. SBRT for Low/Intermediate Risk Disease - Michael Zelefsky, MD, FABS
{{ vm.helper.t('reports.module') }}
Role of Prostate Brachytherapy in Gleason 8-10 Disease - Peter Orio, MD, FABS
{{ vm.helper.t('reports.module') }}
ADT and Brachytherapy: The Good, the Bad, and the Ugly - Mira Keyes, MD, FABS
{{ vm.helper.t('reports.module') }}
Socioeconomic Aspects of Prostate Brachytherapy - Peter Orio, MD, FABS
{{ vm.helper.t('reports.module') }}
ABS Initiatives to Enhance Training the Next Generation of Brachytherapists - Dan Petereit, MD, FABS
{{ vm.helper.t('reports.module') }}
Prostate High Dose Rate Brachytherapy as Boost and Monotherapy - Gerard Morton, MD, FABS
{{ vm.helper.t('reports.module') }}
Post-Activity Survey
{{ vm.helper.t('courses.survey') }}

Shopping Cart

Your cart is empty